T-Heart adds Sarah Sorrel to its Board as Independent Director

– FRANCE, Paris –  T-Heart, a MedTech company, today announced the appointment of Sarah Sorrel to its Board as an independent Director.

“We are excited to have an independent board member with such considerable experience in medtech, and more specifically in the transcatheter heart valve field, joining the board at T-Heart at a key moment for the company. Sarah’s experience and extensive knowledge of healthcare regulations will be an invaluable asset as we advance towards the clinic.” said CEO, Soad El Ghazouani.

About Sarah Sorrel

Sarah Sorrel has more than 30 years of experience in medical device regulation and clinical trials with an emphasis on emerging technologies. She founded and successfully managed MedPass International, a leading European CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access, before its acquisition by ICON plc in 2020. Sarah is American and holds a degree in Engineering and Applied Science from Yale University.

Sarah Sorrel joins the T-Heart Board of Directors when the company is preparing its First Human / Early Feasibility Study, bringing valuable experience and expertise to its execution.

Ms. Sorrel said: “I am honored to join the T-Heart Board of Directors and convinced that tricuspid is the next critical step in the transcatheter heart valve field. I look forward to contributing to T-Heart’s important objective to bring a perfectly adapted and differentiated solution to patients suffering from severe tricuspid regurgitation and hopefully significantly improve their quality of life. “

About T-Heart

T-Heart is a French MedTech company focused on the treatment of Tricuspid Regurgitation, a true medical unmet need. Tricuspid regurgitation is a progressive condition in which blood leaks backward through the tricuspid valve, potentially leading to heart failure and death. The transcatheter tricuspid market represents a $3.0+ billion potential opportunity, although currently, limited treatment options exist to address this market.

T-Heart has developed a truly novel and differentiated transcatheter tricuspid prosthetic heart valve specifically designed for tricuspid heart valve regurgitation, thereby addressing the specific anatomical challenges. Moreover, T-Heart’s unique design enables the interventional cardiologist to replace the diseased tricuspid valve with a simple one-step technique. It allows for broad applicability to a larger patient population with minimal device sizes.

T-Heart was co-founded in late 2018 with iBionext, a company builder and investor that supports and finances the development of companies with a strong technological breakthrough in HealthTech in Paris, France.

Since its inception, T-Heart has assembled an impressive team, comprised of management and external experts, that has successfully proved the concept through pre-clinical testing, and initiated its Q-Sub for EFS with the FDA.

For more information: http://theartvalve.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.